MX2015011760A - Metodos para tratar infecciones en pacientes obesos y con sobrepeso usando antibioticos. - Google Patents

Metodos para tratar infecciones en pacientes obesos y con sobrepeso usando antibioticos.

Info

Publication number
MX2015011760A
MX2015011760A MX2015011760A MX2015011760A MX2015011760A MX 2015011760 A MX2015011760 A MX 2015011760A MX 2015011760 A MX2015011760 A MX 2015011760A MX 2015011760 A MX2015011760 A MX 2015011760A MX 2015011760 A MX2015011760 A MX 2015011760A
Authority
MX
Mexico
Prior art keywords
overweight
antibiotics
nchs
methods
treating infections
Prior art date
Application number
MX2015011760A
Other languages
English (en)
Inventor
Erin M Duffy
Original Assignee
Melinta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51581190&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015011760(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Melinta Therapeutics Inc filed Critical Melinta Therapeutics Inc
Publication of MX2015011760A publication Critical patent/MX2015011760A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere en general, a métodos para tratar las infecciones en pacientes obesos o con sobrepeso usando antibióticos. De conformidad con las estadísticas compiladas por la Encuesta de Examinación de Salud y Nutrición Nacional conducida por el Centro Nacional para Estadísticas de Salud (NCHS), de los Centros Estadounidenses de Control y Prevención de Enfermedades (CDC), en 2009-2010, 35.7% de adultos en los Estados Unidos se encontraron por ser obesos. Ogden, C.L. NCHS Data Brief 2012, 82, disponible en http://www.cdc.gov/nchs/data/databriefs/db 82.pdf (última visita el 2 de Marzo de 2013).
MX2015011760A 2013-03-15 2014-03-14 Metodos para tratar infecciones en pacientes obesos y con sobrepeso usando antibioticos. MX2015011760A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361790179P 2013-03-15 2013-03-15
PCT/US2014/027220 WO2014152332A1 (en) 2013-03-15 2014-03-14 Methods of treating infections in overweight and obese patients using antibiotics

Publications (1)

Publication Number Publication Date
MX2015011760A true MX2015011760A (es) 2016-06-10

Family

ID=51581190

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011760A MX2015011760A (es) 2013-03-15 2014-03-14 Metodos para tratar infecciones en pacientes obesos y con sobrepeso usando antibioticos.

Country Status (14)

Country Link
US (3) US20160058750A1 (es)
EP (1) EP2969004A4 (es)
JP (2) JP6617097B2 (es)
KR (1) KR102237887B1 (es)
AR (1) AR095594A1 (es)
AU (2) AU2014239965A1 (es)
BR (1) BR112015023044A8 (es)
CA (1) CA2904387C (es)
CL (1) CL2015002759A1 (es)
HK (1) HK1219690A1 (es)
IL (1) IL241113A0 (es)
MX (1) MX2015011760A (es)
TW (1) TWI641372B (es)
WO (1) WO2014152332A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201605447A (zh) * 2014-06-20 2016-02-16 美林塔治療學有限公司 處理感染的方法
TN2017000358A1 (en) 2015-02-23 2019-01-16 Theravance Biopharma Antibiotics Ip Llc Doses and methods of administering telavancin
CN107216353B (zh) * 2016-03-21 2020-05-19 山东诚创医药技术开发有限公司 一种头孢洛林酯咪唑盐的精制方法
SG11201811345TA (en) 2016-07-14 2019-01-30 Achaogen Inc Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ593345A (en) * 2008-11-15 2013-04-26 Rib X Pharmaceuticals Inc Antimicrobial composition comprising a quinolone carboxylic acid derivative and a cyclodextrin

Also Published As

Publication number Publication date
EP2969004A4 (en) 2016-09-21
JP2016513689A (ja) 2016-05-16
KR102237887B1 (ko) 2021-04-07
TWI641372B (zh) 2018-11-21
US20240165100A1 (en) 2024-05-23
BR112015023044A2 (pt) 2017-07-18
CA2904387A1 (en) 2014-09-25
US20160058750A1 (en) 2016-03-03
BR112015023044A8 (pt) 2021-09-28
TW201513862A (zh) 2015-04-16
CL2015002759A1 (es) 2016-04-22
WO2014152332A1 (en) 2014-09-25
JP2019196401A (ja) 2019-11-14
EP2969004A1 (en) 2016-01-20
AR095594A1 (es) 2015-10-28
AU2014239965A1 (en) 2015-09-24
JP6617097B2 (ja) 2019-12-04
IL241113A0 (en) 2015-11-30
HK1219690A1 (zh) 2017-04-13
US20220257584A1 (en) 2022-08-18
AU2019200483A1 (en) 2019-02-14
KR20150133762A (ko) 2015-11-30
CA2904387C (en) 2021-12-07

Similar Documents

Publication Publication Date Title
EA201792547A1 (ru) Популяции бактерий для стимуляции состояния здоровья
MX2015010125A (es) Derivados de piridazinona-amidas.
SA518391170B1 (ar) مركبات باي أريل مفيدة لعلاج الأمراض البشرية في علم الأمراض، طب الأعصاب وعلم المناعة
PH12015502588A1 (en) 4`-fluoro-2`-methyl substituted nucleoside derivatives
SG10201811454WA (en) Materials and methods for controlling infections
PH12015502788A1 (en) Antibody formulations and methods
SG10201804306VA (en) THIENO[3,2-d]PYRIMIDINES DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS
NZ751197A (en) Compounds and methods of treating infections
UA115558C2 (uk) Алкілпіримідинові похідні для лікування вірусних інфекцій та подальших захворювань
MX2016002238A (es) Alcoholes de alquilino y metodos de uso.
MX2016002241A (es) Alcoholes de alquinilo y metodos de uso.
EA201491617A1 (ru) Соединения для лечения спинальной мышечной атрофии
MX367897B (es) Derivados de piridazinona macrociclicos.
MY181602A (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
SG10201805267UA (en) Piperazine derivatives having multimodal activity against pain
EA201690323A1 (ru) Способы лечения заболеваний уха у детей
MX2016006975A (es) Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias.
MX2015011760A (es) Metodos para tratar infecciones en pacientes obesos y con sobrepeso usando antibioticos.
EA201591773A1 (ru) Макроциклические ингибиторы rip2-киназы
MX2016008150A (es) Formulaciones de berberina y usos de las mismas.
BR112017026834A2 (pt) composição compreendendo vitaminas b e vitaminas c e seu uso
TR201819263T4 (tr) Nörolojik hastalıkların tedavisi için pantotenat türevleri.
MX367707B (es) Composiciones para uso en la prevencion y el tratamiento de enfermedades neurodegenerativas y dolor.
EA201500736A1 (ru) Пиразолилкарбоксамиды i в качестве ингибиторов crac каналов
EA201500737A1 (ru) Пиразолилкарбоксамиды ii в качестве ингибиторов crac каналов